Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burkimab: Rituximab + Chemotherapy in Burkitt's Lymphoma/LLA-B
NCT00388193Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Aug 2006
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Burkitt lymphoma (BL) and acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Primary endpoint: Efficacy of Rituximab combined with chemotherapy at 1 year. Started Aug 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00388193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388193.